Boundless Bio
BOLD----
Boundless Bio (BOLD)
Boundless Bio, Inc., a clinical-stage oncology company, develops interrogating extrachromosomal DNA (ecDNA) directed therapies for treating patients with oncoge...
- Open
- --
- High
- --
- Low
- --
- Prev. Close
- --
- Volume
- --
- Turnover
- --
- Avg Price
- --
- Bid/Ask Ratio
- --
- Amplitude
- --
- 52wk High
- --
- Volume Ratio
- --
- Turnover Ratio
- --
Boundless Bio Analyst Rating
View MoreForecast & Rating
Jul 1, 2026Price forecast
$4.0058.73%
Forecast & RatingHold
1analysts
- Strong buy0.00%
- Buy0.00%
- Hold100.00%
- Sell0.00%
- Strong sell0.00%
News
- Tip Ranks · 2 days ago, 09:01 PM
Major Investor Quietly Boosts Stake in Emerging Biotech Player
- PUBT · 2 days ago, 06:39 PM
Boundless Bio 10% owner Kevin Tang acquires $11,876 in common shares
- PUBT · Jul 16 at 07:11 PM
Tang Capital’s Kevin Tang reports $154,586 Boundless Bio common share purchase
- PUBT · Jul 13 at 06:06 PM
Tang Capital’s Kevin Tang reports $238,263 purchase of Boundless Bio common shares
- PUBT · Jul 8 at 07:06 PM
Kevin Tang reports $141,464 purchase of 57,210 Boundless Bio common shares
- PUBT · Jul 6 at 04:44 PM
ARCH Venture Fund IX disposes of 16,000 Boundless Bio common shares worth $39,840
